These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37024420)

  • 21. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
    Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
    Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
    Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
    Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
    Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
    J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
    Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
    Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma.
    Michaleas S; Penninga E; Hovgaard D; Dalseg AM; Rosso A; Sarac SB; Jimenez JC; Fernández LL; Fernández CP; Mangas-SanJuan V; Garcia I; Payares-Herrera C; Sancho-López A; Enzmann H; de Castro Lopes Silva MSS; Duarte S; Pignatti F
    Oncologist; 2020 Dec; 25(12):1067-1074. PubMed ID: 33026700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.
    Harousseau JL; Palumbo A; Richardson PG; Schlag R; Dimopoulos MA; Shpilberg O; Kropff M; Kentos A; Cavo M; Golenkov A; Komarnicki M; Mateos MV; Esseltine DL; Cakana A; Liu K; Deraedt W; van de Velde H; San Miguel JF
    Blood; 2010 Nov; 116(19):3743-50. PubMed ID: 20628153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
    Ishida T; Kimura H; Ozaki S; Kubo K; Sunami K; Takezako N; Fujita H; Hayashi T; Kiguchi T; Ohashi K; Yamamoto S; Takamatsu H; Kosugi H; Ohta K; Sakai R; Handa H; Kondo S; Abe Y; Omoto E; Mitani K; Morita S; Murakami H; Shimizu K
    Ann Hematol; 2020 May; 99(5):1063-1072. PubMed ID: 32248251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment.
    Lee SR; Choi H; Lee BH; Kang KW; Yu ES; Kim DS; Park Y; Choi CW; Kim BS; Sung HJ
    Korean J Intern Med; 2019 Nov; 34(6):1333-1346. PubMed ID: 30360024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab: A Review in Combination Therapy for Transplant-Ineligible Newly Diagnosed Multiple Myeloma.
    Syed YY
    Drugs; 2019 Mar; 79(4):447-454. PubMed ID: 30830601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.
    Dimopoulos MA; Richardson PG; Schlag R; Khuageva NK; Shpilberg O; Kastritis E; Kropff M; Petrucci MT; Delforge M; Alexeeva J; Schots R; Masszi T; Mateos MV; Deraedt W; Liu K; Cakana A; van de Velde H; San Miguel JF
    J Clin Oncol; 2009 Dec; 27(36):6086-93. PubMed ID: 19858394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.
    San-Miguel J; Bladé J; Shpilberg O; Grosicki S; Maloisel F; Min CK; Polo Zarzuela M; Robak T; Prasad SV; Tee Goh Y; Laubach J; Spencer A; Mateos MV; Palumbo A; Puchalski T; Reddy M; Uhlar C; Qin X; van de Velde H; Xie H; Orlowski RZ
    Blood; 2014 Jun; 123(26):4136-42. PubMed ID: 24833354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.
    Morabito F; Bringhen S; Larocca A; Wijermans P; Victoria Mateos M; Gimsing P; Mazzone C; Gottardi D; Omedè P; Zweegman S; José Lahuerta J; Zambello R; Musto P; Magarotto V; Schaafsma M; Oriol A; Juliusson G; Cerrato C; Catalano L; Gentile M; Isabel Turel A; Marina Liberati A; Cavalli M; Rossi D; Passera R; Rosso S; Beksac M; Cavo M; Waage A; San Miguel J; Boccadoro M; Sonneveld P; Palumbo A; Offidani M
    Am J Hematol; 2014 Apr; 89(4):355-62. PubMed ID: 24273190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
    Chari A; Rodriguez-Otero P; McCarthy H; Suzuki K; Hungria V; Sureda Balari A; Perrot A; Hulin C; Magen H; Iida S; Maisnar V; Karlin L; Pour L; Parasrampuria DA; Masterson T; Kosh M; Yang S; Delioukina M; Qi M; Carson R; Touzeau C
    Br J Haematol; 2021 Mar; 192(5):869-878. PubMed ID: 33216361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.
    Morabito F; Gentile M; Mazzone C; Rossi D; Di Raimondo F; Bringhen S; Ria R; Offidani M; Patriarca F; Nozzoli C; Petrucci MT; Benevolo G; Vincelli I; Guglielmelli T; Grasso M; Marasca R; Baldini L; Montefusco V; Musto P; Cascavilla N; Majolino I; Musolino C; Cavo M; Boccadoro M; Palumbo A
    Blood; 2011 Nov; 118(22):5759-66. PubMed ID: 21951682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.